Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01BPF
|
||||
Former ID |
DIB016206
|
||||
Drug Name |
Avitriptan
|
||||
Synonyms |
Avitriptan fumarate; BMS-180048
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Migraine [ICD9: 346; ICD10:G43] | Discontinued in Phase 3 | [545344] | ||
Company |
Bristol-Myers Squibb Co
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H30N6O3S
|
||||
Canonical SMILES |
S(=O)(=O)(Cc1cc2c(c[nH]c2cc1)CCCN1CCN(c2c(OC)cncn2)CC1)<br />NC
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 1D receptor | Target Info | Agonist | [534756], [551730] | |
References | |||||
Ref 534756 | Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.Cephalalgia. 1998 Oct;18(8):546-51. | ||||
Ref 551730 | Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.